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ABSTRAK (MALAY LANGUAGE) 
 
PROFIL SEROLOGI DAN UJIAN MOLEKULAR UNTUK VARIAN D DI KALANGAN 
PENDERMA DARAH RESUS NEGATIF DI PERAK 
 
Individu dengan varian D mempunyai potensi untuk menghasilkan anti-D antibodi yang boleh 
menyebabkan tindak balas transfusi hemolitik dan penyakit hemolitik pada janin dan bayi baru 
lahir. Walaubagaimanapun, varian D biasanya tidak dapat dikesan dengan baik dan dilabel 
sebagai Rhesus D (RhD) negatif kerana kelemahan ujian serologi yang sedia ada. Oleh itu, 
adalah penting untuk menyelesaikan masalah percanggahan keputusan ujian serologi akibat 
varian D ini dan seterusnya ujian molekular diperlukan untuk membuat pengkelasan varian D 
secara tepat. Sehubungan itu, tujuan kajian ini adalah untuk mengenal pasti kekerapan varian D 
di kalangan penderma darah RhD negatif dengan menggunakan ujian serologi dan molekul. 
 
Seramai 175 orang penderma darah RhD negatif dari pusat pungutan darah bergerak dan tabung 
darah Hospital Raja Permaisuri Bainun telah dikumpul dari bulan September 2015 hingga Mac 
2016. Melalui ujian serologi, ujian kumpulan darah ABO dan pengelasan RhD telah dilakukan 
dengan menggunakan antibodi monoklonal IgM (TH-28), Diaclone (Diamed) menggunakan plat 
microtitre dan IgM/IgG,EpicloneTM-2 (CSL) menggunakan kaedah jubin dan tiub. Pengelasan 
Rh yang lain pula dilakukan dengan anti-c /C/E/e IgM/IgG, EpicloneTM-2 (CSL). Ujian D 
lemah atau Du telah dilakukan dengan menggunakan kaedah tiub dengan gabungan IgM/IgG 
oleh EpicloneTM-2 (CSL). Ujian molekular menggunakan Polymerase Chain Reaction – 
Sequence Specific Primer (PCR-SSP) untuk mengesan DEL varian (mutasi RHD 1277A atau K 
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(409) K) telah dijalankan ke atas semua sampel, manakala kit BAGene RH TYPE dan kit partial 
D TYPE (kit komersial) telah dijalankan ke atas sampel yang positif ujian Du dan positif RHD 
1277A/K(409) K oleh Polymerase Chain Reaction – Sequence Specific Primer (PCR-SSP). 
 
Kumpulan darah RhD negatif yang paling kerap adalah O (46.9%) diikuti oleh B, A dan AB. 
Fenotip ccddee (81.7%) adalah yang paling kerap di kalangan penderma darah RhD negatif dan 
yang paling kerap dalam semua kaum. Fenotip Ccddee pula kerap di kalangan orang Cina 
(43.8%). Ujian Du menunjukkan, 6 orang (3.4%) merupakan varian D dengan fenotip CcDdee 
(4), CcDDEe (1), and CCDDee (1). Ujian molekular pula mendapati sebanyak 10 orang 
merupakan varian D, iaitu 3 adalah RHD 1277A/K (409) K (semuanya orang Cina), 5 adalah D 
Separa (tak berkelas), 1 adalah DVI Separa jenis III dan 1 adalah RHD-CE(2–9)-RHD. 
 
Kesimpulannya, prevalens varian D di kalangan penderma darah RhD negatif adalah rendah 
(3.4%). Ujian serologi dapat mengesan kebanyakan varian D separa tetapi tidak dapat mengesan 
varian DEL. Hanya ujian molekular mampu mengesan varian DEL (RHD 1277A/K(409)K). 
Kaum Cina yang didapati adalah RhD negatif dengan fenotip Ccddee secara serologi disarankan 
untuk menjalani ujian molekular kerana mempunyai kekerapan yang tinggi untuk DEL 
RHD1277A/K (409)K.  
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ABSTRACT (IN ENGLISH) 
 
SEROLOGICAL PROFILING AND MOLECULAR DETECTION OF VARIANT D IN 
RHESUS NEGATIVE BLOOD DONORS IN PERAK 
 
D variant individual has the potential to cause anti-D production resulting in hemolytic 
transfusion reactions and hemolytic disease of the fetus and newborn. However, D variants are 
usually under detected and mistyped as Rhesus D (RhD) negative due to limitations of the 
available serological tests. Hence it is important to solve serological discrepant cases and further 
accurately classify D variants by molecular testing.  In view of this, the aim of this study is to 
identify the frequency of D variant among the RhD negative blood donors in this population 
using serological and molecular tests. 
 
A total of 175 RhD negative donors were recruited through mobile drives and collection centres 
in Hospital Raja Permaisuri Bainun from September 2015 till March 2016. Serologically, ABO 
blood  grouping and RhD typing was done with monoclonal antibody, IgM (TH-28), Diaclone 
(Diamed) using the microtitre plate and IgM/IgG, EpicloneTM-2 (CSL) using the tile and tube 
method. Other Rh typing was done with the anti-c/C/E/e IgM/IgG, EpicloneTM-2 (CSL). Weak 
D or Du test was done using tube method with IgM/IgG blend, EpicloneTM-2 (CSL). Molecular 
testing using Polymerase Chain Reaction – Sequence Specific Primer (PCR-SSP) to detect DEL 
variant (RHD 1277A or K (409) K mutation)  were done on all samples while BAGene RH 
TYPE kit and Partial D TYPE kit (commercialized kits) were performed on Du positive samples 
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and positive RHD 1277A/ K(409)K samples by Polymerase Chain Reaction – Sequence Specific 
Primer (PCR-SSP). 
 
The most common RhD negative blood group was O (46.9%) followed by B, A and AB. The 
ccddee (81.7%) is the most common phenotype among RhD negative donors and most common 
phenotype in all races. The Ccddee phenotype was common among the Chinese (43.8%). 
Serologically by Du test, 6 (3.4%) were found to be D variant with phenotypes CDe/cde (4), 
CDE/cDe (1), and CDe/CDe (1).  Molecular test revealed a total of 10 donors with D variants in 
which 3 with RHD 1277A/K (409) K (all these belonged to Chinese), 5 with Partial D 
(unclassified), 1 with Partial DVI type III and 1 with RHD-CE(2–9)-RHD.   
 
In conclusion, the prevalence of variant D among RhD negative donors was found to be low 
(3.4%). Serological testing was able to detect most partial D variants but not DEL variants. Only 
molecular testing is able to detect DEL variant (RHD 1277A / K (409) K). Molecular test is 
advised on RhD negative Chinese’s with Ccddee phenotype, since the frequency of RHD DEL 
1277 K (409) K is high among them.  
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1.0 INTRODUCTION 
 
1.1  GENERAL INTRODUCTION 
 
RhD antigen (RhD) was originally discovered in 1939, and was the first clinically important 
blood group to be discovered subsequent to the finding of ABO antigen 39 years earlier. 
(Landsteiner, 2010). Most individuals are designated to be either RhD positive or RhD negative; 
however there is an increased recognition towards the presence of D variants, frequently 
categorized as either weak D, partial D or D-elute (DEL). RhD variants which are inadequately 
defined are still a cause of confusion across blood banks and with transfusionist prompting 
numerous studies in this field. (Denomme et al., 2005) 
 
Among the Rh antigens, D antigen is the most immunogenic followed by c, E, C and e antigen 
(in that order). It is well known to cause immune transfusion reactions. All the antibodies toward 
Rh blood group system are clinically significant as it causes acute and delayed hemolytic 
transfusion reactions and hemolytic disease of the fetus and newborn. 
 
Low or abnormal antigenic expression in D variants such as weak D, DEL and partial D variants 
may result in the failure of detection with certain anti-D reagents, causing these donors to be 
mistyped as RhD negative. The opposite also occurs in some variants (eg: Partial D IIIa) which 
has higher antigenic strength than normal D antigen, causing these donors to be typed as RhD 
positive patients. Subsequently, when these units are given to inappropriate recipients, 
alloimmunization towards antigen D antigen can occur.  However most weak D variants do not 
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spur anti-D formation and can be safely classified as RhD positive. Therefore, correct 
classification of RhD blood group can greatly spare precious RhD negative units and prevent 
unwanted clinical consequences. (Anstee, 2009) 
 
In view of this, RhD status is routinely determined in blood donors, transfusion recipients, and in 
mothers-to-be. Abundant serological techniques and reagents each with different sensitivities 
have greatly complicated RhD typing.  Hence, molecular testing to resolve these discrepancies 
have been introduced in blood banks some parts of the world, especially in populations than 
have higher than average incidence of RhD antigen alloimmunization.(Rizzo et al., 2012) 
 
It is important to realize that monoclonal anti-D reagents have variable reactivity with both 
partial D and weak D types, so they cannot reliably distinguish partial D from weak D 
types(Jones et al., 1995).  Molecular techniques not only can overcome  limitations of serology 
with polyclonal and monoclonal anti-D, they also meet the clinical need to distinguish partial D 
from weak D types and normal RhD from RhD negative and DEL variants such as RHD 
1227A/K(409)K (Denomme, 2011) 
 
RHD 1227A/K(409)K is a DEL variant most commonly found in the Asian population, 
predominantly in Japanese and Chinese population. The DEL variant appears as RhD negative 
phenotype and is routinely identified as RhD negative with routine serological tests and either 
further elution and adsorption testing or molecular testing is needed to identify this variant. 
(Pornlada Nuchnoi, 2014) 
4 
 
This study will help profile the Rh phenotype in the RhD negative donor population in Perak and 
further screen for RHD 1227A/K409K gene and other RhD variants in this population. This will 
help proper categorization and correct supply of blood to recipients. An added benefit will be the 
donors who become recipients will have their RhD antigen screened for possible RHD 
mutations, ensuring they receive blood that doesn’t prompt anti-D formation. 
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2.0  LITERATURE REVIEW 
 
2.1  RhD (Rh) Blood Group System 
 
Blood group antigens were first discovered by Karl Landsteiner in 1900 and 1901 at the 
University of Vienna. These antigens are found to be made up of either sugars or proteins, 
attached to various components on the red blood cell (RBC) membrane that determine an 
individual's blood group. The basic molecule is the H antigen, where its modification results 
in various blood groups. Over 30 blood group systems have been defined, but the two main 
blood group systems are called ABO and RhD (Rh) systems.  The Rh blood group consists 
of about 45 antigens and is the most clinically significant in transfusion medicine next to 
ABO blood system (Avent and Reid, 2000). 
   
 The first Rh gene, RHCE gene was discovered in 1990 and the second RHD gene two 
years subsequently(Flegel, 2007). Both these genes, comprise 10 exons each, are highly 
homologous are located in the short arm of chromosome 1 at (1p34.1-1p36). (Wagner and 
Flegel, 2000). As one of the most immunogenic and clinically significant RBC antigens, Rh 
antigen has been extensively studied. The ability to clone complementary DNA (cDNA) 
and sequence genes encoding the Rh proteins has directed to an understanding of the 
molecular bases connected with some of the Rh antigens (Avent and Reid 2000). RhD and 
RhCE proteins differ by 32-35 out of 416 amino acids and comprise of 10 exons each. They 
encode the RhD and Rh C, C, c, E and e protein that in turn make the Rh antigens: C, c, D, 
E and e (Flegel, 2007).  Rh antigens are expressed only in the membranes of red blood cells 
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and their immediate precursors, unlike other antigens of the blood group system (Avent, 
2000). The function of the Rh complex remains unclear and they may play a role in 
ammonium transportation (Neil D. Avent, 2000). 
 
The difference between C and c antigens is based on the difference of four amino acid 
sequence. They contrast by the amino acid change in Cys16Trp (cysteine at residue 16 
replaced by tryptophan) encoded by exon 1, and Ile60Leu, Ser68Asn, and Ser103Pro 
encoded in exon 2. While the difference between E and e antigens is only one amino acid 
sequence, Pro226Ala, situated on the fourth extracellular loop of the protein in exon 5. RhD 
positive individuals have both RHD and RHCE gene while RhD negative individuals most 
often have a complete absence of the RHD gene but the RHCE gene is intact (Figure 2.1).   
 
The expression of Rh antigen depends on the RHAG to direct these antigens to the RBC 
membrane. None of the Rh antigens are expressed if RHAG is absent. RHAG share about 
35% of their primary sequence with Rh proteins, and is a similar trans-membrane protein. It 
is not polymorphic and does not carry the Rh antigens (Figure 2.2) (Neil D. Avent, 2000). 
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Figure 2.1: Diagram of the RHD and RHCE Locus and Rh Proteins in RBC Membrane.  
(Adapted from Westhoff Connie M., 2007) 
 
 
 
Figure 2.2: Model of topology for RhAG, RhCE, and RhD antigen (Adapted from Westhoff 
Connie M., 2007) 
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2.2  Rh Nomenclature and Rh Phenotype 
 
Generally 8 Rh haplotypes are commonly found: R°, R1, R2, Rz, r, r’, r’’, ry and are 
classified with the Fischer- Race or Weiner nomenclature (Table 2.1). Each haplotype is 
inherited from each parent and expressed in various combinations. This system of Rh 
depiction eases transfusion medicine personnel and laboratory staff in communicating the 
Rh phenotype of a patient or donor (CM, 2004). In the Malaysian population, Rh blood 
group system has shown a diverse distribution among ethnic groups (Table 2.2).  The RhD 
positive individuals were almost 97.5% of the population with the distribution of 99.5% in 
Malays, 98.5% in Chinese, and 91.7% in Indians. The RhD negative phenotype comprises 
of roughly 2% of the population, mostly found in the people Indian ethnicity (7.4%) 
followed by the Malays (5.2%), Chinese (2.3%) and others (2.3%) (Table 2.2)  (Musa, 
2014) 
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Table 2.1: The Phenotypes and Genotypes of the Rh Blood Group System 
 Note: An uppercase R is used to describe haplotypes that produce D antigen and a lowercase r is 
used when D is absent. The C or c and E or e Rh antigens carried with D are represented by 1 for 
Ce (R1), 2 for cE (R2), o for ce (Ro), and z for CE(Rz). The symbols prime (’) and double prime 
(”) are used with r to designate the CcEe antigens; for example, prime is used for Ce (r’), 
doubleprime for cE (r”), and “y” for CE (ry). The R versus r terminology allows one to convey 
the common Rh antigens present on one chromosome in a single term (a phenotype).  (Adapted 
from  Helena Day 2015 ; www.wikipedia.org/wiki/Rh_blood_group_system) 
 
 
 
 
 
 
 
 
 
 
 Rh 
Phenotype 
 Fisher-Race Weiner                  Antigens  
   Dce D,c,e R° 
 RhD  
positive 
 DCe D,C,e 
R
1
 
   DcE D,c,E 
R
2
 
   DCE D,C,E 
R
z 
 
   dce c,e r 
 RhD 
negative 
 dCe C,e r’ 
   dcE c,E r’’ 
   dCE C,E 
r
y
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Table 2.2: Frequencies of Rh Phenotypes among Blood Donors in NBC, Malaysia 
 Malay (%) Chinese (%) Indians (%) 
CDe/CDe 
(R1R1) 
61.5 53.6 50.0 
cDE/cDE 
(R2R2) 
1.0 9.1 0.8 
CDe/cDE 
(R1R2) 
15.0 24.8 12.5 
CDe/cde 
(R1r) 
15.0 6.7 23.4 
cDE/cde 
(R2r) 
2.5 2.9 5.0 
CDe/CDE 
(R1Rz) 
3.5 2.2 0.8 
cDE/CDE 
(R2Rz) 
 
1.0 0 0 
cde/cde 
(rr) 
0.5 0.7 7.5 
   (Adapted from:, Rozi Hanisa Musa, 2012)  
 
 
2.3   Variation of RhD antigen expression 
 
2.3.1 RhD positive 
 
Almost 95% of the world population is Rh positive. Rh positive phenotypes have an intact 
RHD gene and complete expression of the D antigen on the surface of the RBC membrane 
denotes RhD positivity (Figure 2.3).  All 10 exons of the D antigen are expressed and are 
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detected without ambiguity with anti-D. The Rh C, c, e, E antigen is also almost always 
expressed in various combinations(Avent and Reid, 2000) 
 
2.3.2 RhD negative 
 
There are wide racial differences not only in the frequency of Rh phenotypes but also at its 
molecular level. The distribution of the RhD negative phenotype is varied across different 
ethnicities. The RhD negative phenotype is most commonly found in Caucasians (15%), 
less common in Blacks (8%), and rare in Asians (1%).  The Rh CE protein is almost always 
present in RhD negative phenotypes. Inactive or silent RHD gene rather than the entire gene 
deletions are the reason behind RhD negative phenotypes in the African and Asian 
populations as compared to the Caucasians (Wagner, 1995; Daniels, 2013). There are many 
mutated RHD genes and hybrid genes responsible for RhD negative phenotypes and the 
most common Rh negative genotypes are a result of homozygosity or compound 
heterozygosity for an RHD deletion, RHD pseudogene (RHDΨ) (a D gene inactivated by a 
37 bp duplication in exon 4) and RHD–CE–DS gene which is a hybrid of CE and D antigen, 
with an abnormal C antigen and no D antigen produced (Figure 2.3)(Daniels, 2013). In 
Asians, 70% of RhD negative genotypes are due to RHD gene deletion and the rest have an 
intact but poor expression of the RHD gene such as DEL variants(Okuda et al., 1997).  
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2.3.3 D Variant 
 
There are largely 2 classes of D Variant. The first is a quantitative variant where the entire 
RHD gene is intact but has reduced expression levels. This heterogeneity in expression is 
termed weak D and weaker expressions are classified as DEL (Pornlada Nuchnoi 2014). 
The second is a qualitative variant where structural changes to the D protein or antigen 
results in absence of some or many epitopes resulting in partial D and RHD-CE-D hybrid 
genes (Daniels, 2013). Molecular mechanism underlying variant D’s are generally a result 
of single nucleotide polymorphisms (SNP’s), point mutations or genetic recombination’s 
resulting in a RHD-CE-D hybrid gene (Daniels, 2013; Kappler-Gratias et al., 2014). 
 
2.3.3(a) RHD-CE-D hybrid gene  
 
RHD-CE-D hybrid gene is a result of rearrangements and exchanges between RHD and 
RHCE gene (Kappler-Gratias et al., 2014). Since the two Rh genes are closely situated with 
an inverted orientation, this enhances opportunity for genetic exchange. Exchanges between 
these two genes encode hybrid proteins that may have RhCE and RHCE residues in RhD 
protein. These generate new antigens and alter or weaken expressions of the conventional 
RhD antigens. (Figure 2.3)  (Avent and Reid, 2000) 
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Figure 2.3: Representation of the genomic organization of the RhD positive haplotype and 3 
RhD negative haplotypes. (Adapted from Belinda K, 2000) 
 
2.3.3(b) Partial D variant 
 
Partial D variant is a qualitative variant, where either some or many epitopes are lacking on 
the D antigen. Individuals who lack certain parts of the D antigen may be immunized with 
normal D RBC’s and produce antibodies to the missing parts. These antibodies behave as 
anti-D in routine serological testing. Analysis of epitopes of the D antigen on partial D red 
cells by monoclonal antibodies and sequencing of genes encoding the D antigen led to 
classification of partial D antigens into categories. These categories were initially numbered 
with Roman numerals from DII (DI was made obsolete) to DVII, and further molecular 
analysis discovered other partial D variants such as DBT, DFR, and DHAR The molecular 
basis of partial D is shown in (Figure 2.4). The strength of reactivity of partial D antigens 
with the anti-D that react with them varies. Some reactions may be weaker than that of 
normal RhD positive cells (e.g. DVI), similar to normal RhD positive cells (e.g. DIII), or 
can even seem to have raised D expression (e.g. DIVa) (Daniels, 2013).  Almost all Partial 
D can produce anti-D with partial DVI to be most commonly reported(Zabern et al., 2013). 
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Figure 2.4 : Molecular basis of Partial D phenotypes(Avent and Reid, 2000). 
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2.3.3(c) Weak D variant. 
 
Weak D variant is a result of normal RHD sequence but with severely reduced expressions. 
Genetic analysis of the weak D phenotype, demonstrated a standard RHD sequence but with a 
reduced expression indicating a defect at transcription or pre-mRNA processing levels. Recent 
research on weak D RBCs found missense mutations within the transmembrane or cytoplasmic 
domains of RhD antigen(Garratty, 2005). Molecular basis of weak D variants is shown in 
(Figure 2.5).The normal number of D antigen sites in normal red blood cell (RBC) is 10,000- 
30,000 antigen sites and 1500 to 7000 sites for weak D and in DEL RBC’s is estimated to be less 
than 40 (Nagl, 2014; Pornlada Nuchnoi, 2014). Individuals with weak D type 4.2-11 and weak D 
type 15 can be immunized to make anti-D and should be treated as RhD negative. These weak D 
types should be transfused with RhD negative red blood cells. Individuals with weak D types 1, 
2, 3, 4.0, 4.1 and 5 can be treated as Rh positive and be transfused by Rh positive red blood cells 
(Rizzo et al., 2012).  
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Figure 2.5: Molecular basis of weak D phenotypes.  
Note: This figure depicts missense mutations in the RHD gene associated with weak D 
phenotypes. The locations of these mutations on the predicted topology of the RhD protein are 
depicted as checkered ovals; the D specific amino acids are shown as open ovals. Most of the 
missense mutations are located within nonconserved membrane spans (gray) and cytoplasmic 
regions. Regions of conserved Rh protein family sequence are indicated as black rectangles. 
(Adapated from: Neil D. Avent and Marion E. Reid, 2000) 
 
 
2.3.3(d) DEL variant 
 
Some  RhD antigen are so weakly expressed in blood donors and is below the detection limit of 
standard serological screening platforms at Blood Banks, have been termed ‘DEL’ or D-elute. 
The tern D-elute or ‘DEL’ is from anti–D adsorption-elution test performed to identify this D 
variant. 
 
RhD blood group variant DEL is most commonly reported in individuals of Japanese and 
Chinese ethnicity and generally in East Asians. (Pornlada Nuchnoi, 2014). The reported 
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prevalence is almost 30% in Asian RhD negative donors. Detailed examination and epitope 
mapping of the D antigen using the adsorption elution test and with different monoclonal 
antibodies have been done. Monoclonal antibodies detected that the RHD (IVS3+1g>a) allele, 
do not have a major proportion of normal D epitopes, expressing only epitopes 2 and 5. In 
contrast, RHD 1227A K409K, RHD (IVS5-38del4), RHD(X418L), and RHD (M295I) were 
found to possess all tested D epitopes suggesting a presence of a complete D antigen albeit with 
poor expressions. (Körmöczi et al., 2005) 
 
The molecular mechanism of  DEL variant is unclear but can be mainly explained is through 
nucleotide modifications in the trans membrane and cytosolic domains of the RhD protein 
(Figure 2.6) (Pornlada Nuchnoi, 2014). So far, 17 RHD alleles (subtypes) that encode DEL 
phenotypes have been described (Nagl, 2014).  
 
Due to the complexity of RHD gene it is challenging to detect the RHD architecture and 
associated modifier genes in DEL variant in different genetic backgrounds. One of the most 
common DEL alleles in the Caucasian population is IVS3+1 g>a (splice site mutation)(Daniels, 
2013),  whereas in East Asians the most frequent DEL allele RHD 1227A/K409K (Gu et al., 
2014). Various populations report different frequencies of DEL-associated alleles. (Table 
2.3)(Pornlada Nuchnoi, 2014)  
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Table 2.3:  Distribution of DEL-Associated Alleles among Different Ethnic Groups  
DEL-Carrying Individuals Per Ethnic Group, No. 
 
DEL Allele 
 
Taiwanese 
(n = 94) 
Chinese 
(n = 26) 
Chinese 
(n = 279) 
Danish 
(n = 13) 
German 
 
(n=47) 
K409K 94 25 268 … 4 
IVS7+152A … 1a … … … 
Hybrid alleleb … … 3 … 1 
3G>A … … 4 … … 
R10W … … 1 … … 
L18P … … 1 … … 
L84P … … 1 … … 
A137E … … 1 … … 
L153P … … … … 1 
G212R … … … … 1 
Y401X … … … … 1 
X418L … … … … 2 
IVS2–2A>G … … … 2 … 
IVS8+1G>A … … … 1 … 
659delG … … … 2 … 
885G>T … … … 1 14 
896T>C … … … 1 … 
IVS7–2A>C … … … 1 … 
IVS3+1g>a … … 
 
1 16 
93_94insT … … 
 
1 2 
147delA … … 
 
… 4 
a : Heterozygote of K409K and IVS7+152A  b : RHD-CE-D hybrid. (Adapted from: Pornlada 
Nuchnoi 2014) 
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Figure 2.6:  Molecular background of known DEL alleles. Note: An in-scale scheme of the RHD 
gene is depicted, with introns shown at 1/10th of their length. Exon count and exon and intron 
length in base pairs (bp) are given. (Pornlada Nuchnoi, 2014)  
 
 
2.4  RhD 1227A>G mutation 
 
In ethnic Eastern Asians the RHD 1227A/K409K is the most common single nucleotide 
polyphormism mutation resulting in the DEL variant. RHD 1227A/K409K is related to a splice 
site in exon 9 of RHD gene, where the nucleotide guanine is replaced with alanine. This DEL 
variant is greatly associated with the C phenotype (CDe or cDE haplotypes)(Table 2.4) 
(Pornlada Nuchnoi, 2014) 
In a study done in Malaysia 12 out of 17 donors of Chinese ancestry, belonging to the Ccee 
phenotype were found to be positive for the RHD 1227A/K409K or RhD DEL 1227A>G 
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mutation(Tay Za Kyaw, 2012). A precedent study that supports these findings is a study on the 
Molecular basis of DEL phenotype in the Chinese population conducted by Juan Gu et all 
centered in southeast China. Among 165 samples of RhD negative donors and 41(24.58%) of 
them were typed DEL phenotype by the Indirect AHG test and the adsorption-elution test. 
Further molecular test with sequence specific primers revealed 90.2% DEL samples were 
harboring the RHD1227A/K(409)K variant. The remaining samples noted to have RHD-CE-D 
hybrid alleles (Gu et al., 2014) . Many other studies exploring the genetic basis of the DEL 
variant showed similar results. (Srijinda et al., 2012; Sun et al., 2008). 
 
 
Table 2.4: RHCE Phenotypic distribution of DEL among distinct ethnic populations  
RHCE Phenotype 
Population Frequency 
Chinese Taiwanese Taiwanese German 
Ccee 83.51% 83% 83.3% 82.97% 
CCee 12.19% 15% 14.3% 10.65% 
CCEe 0.36% 1% 0.8% … 
CcEe 3.23% 1% 1.6% … 
ccEe 0.72% … … 6.38% 
ccee … … 2.13% … 
   (Adapted from: Pornlada Nuchnoi 2014) 
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Table 2.5: D variants and Rh considerations for transfusions  
   (Adapted from : Krishna Oza, 2011)      
RhD 
Phenotype 
D antigen 
sites 
Formation 
of anti-D 
Reactivity 
with anti – D 
(monoclonal) 
Genetic 
Basis 
Detection Rh 
consideration 
for 
transfusion  
Rh 
Positive 
10,000-
30,000 
 
No Strong Complete 
RHD gene 
present 
Reacts at 
immediate 
spin 
RHD 
positive 
D variants       
Weak D 1,500-
7,000 
No, 
except D 
type 
4.2,11 and 
15 
Weak Point 
mutations in 
intracellular 
or 
cytoplasmic 
region of 
RHD 
Reacts at 
AHG phase 
Can be 
considered 
RhD positive 
for most 
cases 
Partial D 10,000-
30,000 
(mutated) 
Yes Strong Point 
mutations in 
the 
extracellular 
region of 
RHD 
Forms anti-
D 
following 
transfusion 
RhD 
negative 
DEL 22-30 Yes Negative RHD 
mutation and 
altered 
epitopes 
Formation 
and elution 
of anti-D 
RhD 
negative 
RHD CE 
D hybrid 
gene 
reduced Yes Strong : 
DHAR, cecf 
antigen 
Weak : ceRT, 
ceSL antigen 
Presence of 
D like amino 
acid 
sequence in 
Rhce protein 
reacting to 
some 
monoclonal 
anti-D 
Negative 
with some 
and 
positive 
with some 
monoclonal 
antibodies 
RhD 
negative 
Rh 
negative 
none Yes 
 
Negative No RHD 
gene present 
 RhD 
negative 
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2.5 Clinical importance of D variants in patients and donors. 
 
D variants are clinically important because there have been reported cases where RhD positive 
patients have produced anti-D with transfusion from RhD positive RBC’s and RBC’s from 
seemingly RhD negative donors have stimulated anti-D production in RhD negative patients. 
There are also cases where individuals show discrepant RhD typing when tested at different 
centres, for example RhD negative at Hospital A but RhD positive at Hospital B. Upon further 
investigation, these patients and donors were discovered to be D variant (Oza, 2015).  
 
Individuals with RhD variant have been reported to experience acute and delayed hemolytic 
transfusion due to mislabeling of RhD type. In the field of obstetrics, women with D variant are 
known to produce anti- D with a potential for hemolytic disease of fetus and newborn (HDFN). 
It is important to appropriately classify D status so that women with D variants capable of 
making anti-D can be offered Rh IG prophylaxis (Dehua Wang, 2010).  
 
Weak D types 1–3 are the most frequent of those variants with a ‘weak D’ designation, 
representing about 93% of those D variants in a Caucasian population (Wagner et al, 1999). 
Frequencies vary in different populations in Asia the most common variant D is DEL variant 
amounting to 30% of RhD negative individuals. As mentioned earlier, individuals with weak D 
type 4.2-11 and weak D type 15 are commonly found to produce anti-D. Almost all partial D 
variants can make anti-D, but the clinically important ones are DAR, DFR, and DAU and 
categories DIIIa, DVa, and DVI(Table 2.5 and Table 2.6) (Denomme et al., 2005; Oza, 2015). 
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DEL variants found to produce anti-D include RHD 1227A K409K, RHD (IVS3 + 1G>A) allele, 
DEL-5, DEL-ex 8 del(Daniels, 2013; Nagl, 2014; Xu et al., 2015) 
 
 
Table 2.6: Some D variants associated with production of alloantibodies to RhD antigen. 
Partial D Weak D DEL 
DII DFL Weak D type 1a DEL-5 
DIII DFR Weak D type 2a DEL-ex 8 del 
DIVa DFV Weak D type 4 RHD 1227A K409K, 
DIVb DHAR Weak D type 11 RHD (IVS3 + 1G>A) 
DV DHMI Weak D type 15  
DVI DMH Weak D type 21  
DVII DMI Weak D type 57  
DAR DNAK Weak D type 2a  
DAU DNB Weak D type 4  
DBT DOL Weak D type 21  
DVII DFV Weak D type 57  
DAR DHAR   
                    (Adapted from : Geoff Daniels,2013) 
 
 
